Drug Development Pipeline
Inhaled Levofloxacin (Quinsair™)
Inhaled levofloxacin (Quinsair™) is a formulation of the antibiotic levofloxacin for the management of chronic lung infections caused by Pseudomonas aeruginosa and other bacteria.
Inhaled levofloxacin has been approved in the European Union and Canada for adults with CF. A Phase 3 trial in the United States has been completed. No further development in the U.S. is planned at this time.
The program was sponsored by Chiesi and partially supported by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
Recent Inhaled Levofloxacin (Quinsair™) Studies
Closed to Enrollment
Inhaled Levofloxacin (MP-376) pediatric safety study (MPEX 206)
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More